



# Biotech Daily

Monday September 2, 2024

*Daily news on ASX-listed biotechnology companies*

- \* AUGUST BDI-40 SLIPS 1.5%; ASX FLAT; BIG CAPS UP 0.3%; NBI UP 1%
- \* TODAY: ASX UP, BIOTECH DOWN: MEDICAL DEVELOPMENTS UP 14%;  
- MEDADVISOR DOWN 10%
- \* MTP CONNECT \$28.5m ACCELERATOR FOR HEART DISEASE, DIABETES
- \* CORRECTION: TELIX
- \* WEHI IMMUNOTHERAPY FOR BRAIN CANCER, IN-VITRO, IN MICE
- \* CARDIEX REVENUE UP 137% TO \$10.9m; LOSS DOWN 59% TO \$8m
- \* HYDRIX REVENUE DOWN 19% TO \$10.6m; LOSS UP 2,308% TO \$9.6m
- \* BIOXYNE REVENUE UP 81% TO \$9.3m; LOSS UP 587% TO \$13.5m
- \* INVION REVENUE DOWN 10% TO \$3.7m; LOSS UP 249% TO \$5.6m
- \* CSL TO SELL RUIDE PLASMA FOR \$274m TO CHENGDU RONGSHENG
- \* ENLITIC \$22.5m PLACEMENT, PLAN FOR \$1.3m TO BUY LAITEK
- \* ADALTA RECEIVES \$1m FROM NEW LIFE SCIENCES, MEURS
- \* IMUGENE 3 OF 10 COMPLETE AZER-CEL LYMPHOMA RESPONSES
- \* EMYRIA MDMA FOR PTSD 'PROMISING' INTERIM RESULTS
- \* MAYNE: CANADA COURT DISCONTINUES CIVIL CASE; US CONTINUES
- \* PLATINUM REDUCES TO 14% OF ADALTA
- \* MICROBA LOSES CO-CO-SEC PETER WEBSE
- \* DR SCROFANI REPLACES RACE DIRECTORS MARY HEANEY, PHIL LYNCH
- \* CAMBIUM CEO KAROLIS ROSICKAS ON \$480k PA
- \* ONCOSIL'S PETER HALL DIRECTOR APPOINTMENT DELAYED
- \* TISSUE REPAIR: 'NO MEETING REQUISITION SERVED'

## MARKET REPORT

The Australian stock market was up 0.22 percent on Monday September 2, 2024, with the ASX200 up 18.0 points to 8,109.9 points. Fourteen of the Biotech Daily Top 40 stocks were up, 19 were down and seven traded unchanged.

Medical Developments was the best, up 5.5 cents or 13.6 percent to 46 cents, with 93,055 shares traded. Imugene improved 9.7 percent; Amplia was up 4.2 percent; Compumedics climbed 3.2 percent; Avita, Curvebeam, Cynata, Mesoblast, Starpharma and Syntara rose more than two percent; with Clarity, Cochlear, Cyclopharm, Polynovo, Pro Medicus and Resmed up by less than one percent.

Medadvisor led the falls, down 4.5 cents or 10.1 percent to 40 cents, with 4.4 million shares traded. Actinogen lost 8.9 percent; Neuren shed 7.2 percent; Emvision was down 5.1 percent; Dimerix, Genetic Signatures and Proteomics fell four percent or more; Opthea and Telix were down more than three percent; Alcidion, Immutep, Paradigm, Percheron and SDI shed more than two percent; Nanosonics and Resonance were down more than one percent; with Aroa, Clinuvel, CSL and Micro-X down by less than one percent.

## MTP CONNECT

MTP Connect says it will provide \$28.5 million for drugs and devices for cardio-vascular disease and the complications of both type 1 and type 2 diabetes.

MTP Connect said that funds were from the Federal Government Medical Research Future Fund with co-operation from industry partners CSL and Roche Diagnostics via the Targeted Translation Research Accelerator (TTRA).

MTP Connect chief executive officer Stuart Dignam said the investment would open for expressions of interest later this year.

“Our new TTRA initiative, covering both therapeutics and devices, is designed with translation and commercialization in mind, making all the difference for [small and medium -sized enterprises] with moonshot ambitions,” Mr Dignam said.

“Supporting translation of research into the clinic will also develop domestic research and development talent skilled in commercialization, improve healthcare options and create more jobs in our life sciences sector,” Mr Dignam said.

“Our experience running similar accelerator programs has revealed that the value of non-dilutive funding – along with access to industry knowledge, mentoring, market expertise and commercialization skills – is a powerful multiplier for [small and medium -sized enterprises] that truly boosts their chances of success,” Mr Dignam said.

“While Australia is recognized as a global research leader, ranking in the top 10 of the Global Innovation Index, we slip down to 30th for outputs from that research,” Mr Dignam said.

“By backing Australian [small and medium -sized enterprises] with access to leading industry expertise, as well as funding, we’re maximizing chances for commercialization success and working to lift Australia up the global innovation league table,” he said..”

CSL executive Prof Bronwyn Kingwell said CSL supported research commercialization which “dovetails nicely with our long-term commitment to supporting Australia’s biotech ecosystem”.

MTP connect said that the TTRA program would call for expressions of interest by late September 2024.

## BIOTECH DAILY TOP 40 INDEX (BDI-40)

The last month of Australian Winter – with Melbourne in full Spring bloom – was mixed, with the August Biotech Daily Top 40 Index (BDI-40) down 1.5 percent after nine months of consecutive gains.

The benchmark ASX200 was even at 8,092 points, the Nasdaq Biotechnology Index (NBI) was up 0.8 percent; the collective value of the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) edged up 0.3 percent to its highest value on record at \$220,711 million, while Cannabis Corner continued to fall, down 0.75 percent.

Resmed's \$4,756 million, or 10.0 percent rise to \$52,484 million, just compensated for CSL's 0.6 percent fall to \$148,808 million and Cochlear's 14.1 percent loss to \$19,419 million, following three consecutive months of gains.

For the year to August 31, the BDI-40 was up 69.0 percent, the NBI improved 18.6 percent, the three Big Caps were up 17.9 percent and the ASX200 rose 10.8 percent.

In August, 17 of the BDI-40 companies were up, eight by more than 10 percent; 21 fell, with 13 down by more than 10 percent, and two were unchanged.

Again, Pro Medicus added the most - \$364 million in August - but Amplia was the percentage best, up \$18 million or 120 percent to \$33 million, followed by Opthea (36.1%), Medical Developments (27.8%), Percheron (20.0%), Immutep (17.4%), Resonance (16.0%), Clarity (14.9%) and Imugene (11.3%).

Last month's 50 percent best, Atomo, led the August falls, down \$11 million or 45.8 percent to \$13 million, followed by Actinogen (36.8%), Impedimed (22.4%), Cynata (22.2%), Micro-X (22.2%), Neuren (21.2%), Aroa (13.4%), Avita (12.5%), Cyclopharm (12.1%), Medadvisor (11.9%), Polynovo (11.5%), Nova Eye (11.1%) and Curvebeam (10.7%).


The 12 companies that comprise Cannabis Corner slipped a collective 0.75 percent in August to \$265 million – a very long way from the \$1.9 billion peak in 2021 – and down 45.1 percent for the year to August 31, 2024. Bioxyne improved 91.7 percent to \$23 million, Emyria fell 23.5 percent to \$13 million, three were unchanged and the rest had small falls or rises.

Outside the BDI-40, several companies in the Third 20, were knocking on the BDI-40 door; including Argenica, Bcal, Botanix and EBR, with Control Bionics, Oncosil and Radiopharm in recovery.


LTR had a 268.6 percent bump from \$65 million to a market capitalization of \$159 million, following news that its vardenafil-based (Levitra) Spontan nasal spray for erectile dysfunction had Australian Therapeutic Goods Administration special access scheme and authorised prescriber approvals.

On the Nasdaq, Kazia recovered 11.8 percent to \$19 million, but Bionomics, Eyepoint (Psivida), Incannex and Redhill (with Australian assets) all fell. Queensland's Protagonist added \$277 million or 8.0 percent to \$3,735 million.


**BDI-40 v ASX200 Jun 30, 2006 to Aug 31, 2024- Adjusted**



**Big Caps \$m (Cochlear, CSL, Resmed) Aug 31, 2019 – Aug 31, 2024**



**BDI-40 (\$m) v S&P ASX 200 – Jan 31, 2020 – Aug 31, 2024 (Pre-Covid to date)**



## CORRECTION: TELIX PHARMACEUTICALS

Friday's edition incorrectly said that TLX591 was actinium-based, whereas it actually uses lutetium.

The Friday sub-editor was confused having previously read the history of Actinogen, which was based on actinium and has been dispatched to a distant Pilbara, Western Australia mining school to learn the difference. He is not expected to return.

Telix was down 60 cents or 3.2 percent to \$18.01 with 1.7 million shares traded.

## THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

The Walter and Eliza Hall Institute says it has identified a "promising new two-in-one treatment" to target, destroy and defend against glioma brain cancers.

WEHI said that a chimeric antigen receptor T-cell (CAR-T) immunotherapy had shown an ability to eliminate glioma cells and had "potential to strengthen the immune system to prevent future tumor growth, which were "two significant advances that could revolutionize the way these lethal cancers are treated".

The Institute said that in Australia, one person was diagnosed with brain cancer every five hours and there was no cure "and current therapies for severe brain cancers like gliomas are largely ineffective, leaving patients with few options"

WEHI said that CAR T cell therapy had "shown promise for brain cancer treatment, [but] finding the right proteins to target on brain cancer cells has been a major hurdle".

The Institute said that the study showed that the EphA3 protein, found on the surface of high-grade glioma cells, "could be a key target for CAR-T-cell therapy".

WEHI said that the research, titled 'EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses' was published in the Journal for Immunotherapy of Cancer and the full article was available at:

<https://jitc.bmj.com/content/12/8/e009486>.

The Walter and Eliza Hall Institute lead researcher Prof Misty Jenkins said "the potential impact of this discovery is profound on many levels".

"This new way to treat gliomas could offer a potential lifeline for patients," Prof Jenkins said. "Our research has shown that EphA3-targeted CAR-T-cells can effectively seek out and eliminate glioma cells, both in lab tests and animal models."

"This therapy not only targeted and killed the cancer cells, but also triggered a long-lasting immune response, preventing future tumor growth," Prof Jenkins said.

"We never expected a two-in-one breakthrough that could offer such life-saving possibilities," Prof Jenkins said. "This is a significant development because gliomas are incredibly challenging to treat, and current options are limited."

"Most importantly, this could mean longer survival times for patients and improved quality of life, giving hope to those affected by these aggressive cancers," Prof Jenkins said.

"CAR-T-cell therapy is clever because it uses a patient's own immune cells and engineers them to recognize and kill the tumor, with no long-term side effects," Prof Jenkins said.

"The tricky nature of brain cancer means that traditional methods don't work - chemotherapy is ineffective, and radiation kills cancerous and healthy brain tissue," Prof Jenkins said.

"This recent discovery is further evidence that immunotherapy is a powerful force that can help overcome many cancer challenges that were previously considered insurmountable," Prof Jenkins said.

WEHI said that the project team was "hopeful that future clinical trials for EphA3-targeted CAR-T-cell therapy could lead to the development of a treatment that not only kills and halts cancer growth, but also provides lasting immunity".

## CARDIEX

Cardiex says revenue for the year to June 30, 2024 was up 136.9 percent to \$10,905,636, with net loss after tax down 59.2 percent to \$7,748,780.

Cardiex said revenue was from sales of its hypertension and vascular disease devices and Sphygmocor central blood pressure technology.

The company said diluted loss per share fell 73.8 percent to 3.8 cents, net tangible asset per share turned from negative 0.96 cents to a positive 0.88 cents, and it had cash and equivalents of \$481,429 at June 30, 2024, compared to \$716,319 the prior year.

Cardiex was untraded at 5.5 cents.

## HYDRIX

Hydrix says revenue for the year to June 30, 2024 was down 19.4 percent to \$10,608,574 with net loss after tax up 2308.2 percent to \$9,558,852.

Hydrix said \$10,607,103 in revenue was from Hydrix Services, which provided medical technology consulting services, with \$1,471,000 from its Guardian heart device business.

The company said revenue for its Hydrix Services subsidiary fell by \$2.5 million due to “client projects being completed while certain new client projects ... yet to commence”, with the fall in revenue larger than reduction in operating costs, as well as the Hydrix Services’ expansion into Europe and the US.

Hydrix said that diluted loss per share was up 2,111.8 percent to 3.76 cents, net tangible assets per share turned from positive 1.14 cents to a negative 1.53 cents, and it had cash and equivalents of \$914,274 at June 30, 2024, compared to \$1,153,080 at June 30, 2023. Hydrix was unchanged at 1.1 cents.

## BIOXYNE

Bioxyne says revenue for the year to June 30, 2024 was up 80.7 percent to \$9,325,020, with net loss after tax up 587.2 percent to \$13,500,723.

Bioxyne said revenue included a year of sales from the Breathe Life Sciences business and its marijuana-based products, as well as its probiotic *Lactobacillus fermentum*.

The company said the loss included a non-cash write down of the “goodwill on the reverse acquisition of Breathe Life Sciences and Bioxyne” to the amount of \$11,568,010 and a loss of \$526,072, for a trading loss of \$1,406,641 (BD: Dec 19, 2022).

The company said diluted loss per share rose 366.7 percent to 0.70 cents, net tangible assets per share fell 16.7 percent to 0.15 cents, and it had cash and equivalents of \$1,027,989 at June 30, 2024, compared to \$3,845,969 at June 30, 2023.

Bioxyne was up 0.1 cents or 9.1 percent to 1.2 cents with 2.5 million shares traded.

## INVION

Invion says revenue for the year to June 30, 2024 was down 10.0 percent to \$3,694,256 with net loss up 248.5 percent to \$5,627,765.

Invion said its revenue came from the Hong Kong-based RMW Cho Group under their research and development services agreement for the Photosoft light therapy.

The company said the increased loss was “mainly driven by provision for bad and doubtful debts of \$3,696,720 taken during the year”, net tangible assets fell 75.0 percent to 0.02 cents, diluted loss per share rose 200 percent to 0.09 cents and it had cash and equivalents of \$783,526 at June 30, 2024 compared to \$4,084,903 at June 30, 2023.

Invion was unchanged at 0.3 cents with 1.4 million shares traded.

## CSL

CSL says it will sell its Wuhan-based Rui De Biologics plasma collection and fractionation operations to Chengdu Rongsheng for \$US185 million (\$A273.7 million).

CSL said Ruide developed, manufactured and commercialized plasma products for China, with five plasma collection centres and one plasma manufacturing facility in Wuhan.

The company said it did not expect the sale to the Chengdu, China-based Chengdu Rongsheng to materially impact its operations or its overall business in China, with the transaction “expected to close by the end of calendar year 2024”.

CSL chief executive officer Dr Paul McKenzie said “the Ruide divestiture is a strategic decision by CSL to serve patients in China through a different approach that better aligns with our long-term strategy and CSL’s scale and capabilities across geographies”.

Dr McKenzie said that CSL was committed to serving the needs of patients across China”.

CSL fell \$1.42 or 0.5 percent to \$305.74 with 441,912 shares traded.

## ENLITIC

Enlitic says it has “firm commitments” to raise \$22.5 million at 5.0 cents a share in a placement and share plan for \$1.3 million, partly to pay for its Laitek acquisition.

Enlitic said the raising at 5.0 cents per Chess depositary interests was a 50.1 percent discount to the 5-day volume-weighted average price, with the funds going to its acquisition of medical imaging data migration company Laitek Inc (BD: Aug 29, 2024).

The company said the share plan had a record date of August 30, 2024, would open on or about October 21 and close on November 8, 2024.

Enlitic fell 3.2 cents or 34.8 percent to six cents with 1.3 million shares traded.

## ADALTA

Adalta says it will receive the second investments, totalling \$1.0 million, from its institutional placement to New Life Sciences Capital and Meurs Group.

In April, Adalta said it would raise up-to \$3,000,000 in a draw-down equity facility with New York’s Bergen-managed New Life Sciences Capital LLC and up-to \$700,000 from existing shareholder the Meurs Group (BD: Apr 29, 2024).

Today, Adalta said New Life Sciences would pay an additional \$700,000 by November 2, 2024, with Meurs Group to invest \$300,000 by September 30, 2024.

Adalta was up 0.1 cents or 4.8 percent to 2.2 cents.

## IMUGENE

Imugene says it has “three complete responses” of the 10 patients treated so far in its phase Ib trial of azer-cel for large B-cell lymphoma, with azer-cel safe and tolerable.

In 2023, Imugene said it would acquire ‘azer-cel’, or azercabtagene zapreleucel, CD19 chimeric antigen receptor T-cell therapy for blood cancers (BD: Aug 16, 2023).

Today, Imugene said it studied patients who had failed more than four prior treatments, and that six patients in cohort A were treated with azer-cel and lympho-depletion chemotherapy, with four patients in cohort B treated with azer-cel, lympho-depletion and interleukin-two; with the first two patients treated achieving a complete response, with one response lasting more than 90 days and the other more than 120 days.

The company said all patients in cohort B were ongoing, with one patient awaiting evaluation, and additional patients to be enrolled.

Imugene was up 0.6 cents or 9.7 percent to 6.8 cents with 301.6 million shares traded.

## [EMYRIA](#)

Emyria says interim analysis of the first eight patients in its MDMA-assisted therapy program for post-traumatic stress disorder shows an improvement in symptoms.

Emyria said patients with moderate to severe post-traumatic stress disorder (PTSD) were tested through 'post-traumatic stress disorder checklist for DSM-5 (PCL-5) scores, based on a self-administered, 20-item self-reported assessment, with an average reduction of 33 points in symptom severity and "many" patients reaching scores below 30, which was a "key threshold indicating substantial symptom reduction".

Last year, the company said it had recruited the first of up-to 70 patients in its phase IIb trial of 3,4-methylene-dioxy-meth-amphetamine (MDMA) for post-traumatic stress disorder and in October said it had dosed the first patient (BD: Oct 9, 2023).

Today, Emyria said all patients also reported gains in quality of life, with a mean improvement of 22 points according to 'recovering quality of life' (Reqol) scoring.

Emyria chief executive officer Dr Michael Winlo said the results "highlight the significant potential of this approach for PTSD care and provide an early indication of its effectiveness in real clinical settings beyond controlled trials".

The company said the results would be presented at the West Australia branch conference of the Royal Australian and New Zealand College of Psychiatrists between September 6 and 7, 2024.

Emyria was up 0.3 or 9.4 percent to 3.5 cents with 1.2 million shares traded.

## [MAYNE PHARMA GROUP](#)

Mayne says Canada's Federal Court has issued an order discontinuing the civil action against it and a "number of generic companies".

Mayne said it was subject to a proposed class action in Canada making allegations of anti-competitive conduct against several generic pharmaceutical companies regarding the sale of generic drugs in Canada.

The company said the decision to discontinue the Canadian action against it did not impact ongoing civil complaints made on the same basis in the US, which it continued to "strongly defend the allegations made in these remaining civil complaints".

In its Full Year statutory accounts, Mayne said the settlement amount was "\$38 million, inclusive of interest and costs, of which approximately \$4.7 million is funded by insurance, with the remainder to be paid from Mayne Pharma's cash reserves".

Mayne fell 14 cents or 2.7 percent to \$5.11 with 365,867 shares traded.

## [ADALTA](#)

Platinum Investment Management says it has reduced its substantial shareholding in Adalta from 87,863,759 shares (14.75%) to 81,891,886 shares (13.75%).

The Sydney-based Platinum said that between July 2 and August 29, 2024 it sold shares, with the single largest sale on July 5 of 982,365 shares for \$24,745 or 2.5 cents a share.

## [MICROBA LIFE SCIENCES](#)

Microba says Peter Webse has resigned as joint company secretary, effective from August 31, 2024, with James Health continuing as company secretary.

The company said its board extended "its sincere gratitude to Mr Webse for his contributions and wishes him every success in his future endeavors".

Microba was up half a cent or 2.8 percent to 18.5 cents.



### RACE ONCOLOGY

Race says Dr Serge Scrofani will replace directors Mary Harney and Phil Lynch; with Dr Pete Smith promoted to chair and Dr Daniel Tillett to managing-director.

Race said Dr Scrofani would be a non-executive director, and had more than 28 years in the healthcare sector, including as CSL's head of strategy and corporate development, was healthcare advisory firm Poplar Advisory principal, a director of the Burnet Institute and the Centre for Eye Research, and a founder of private equity firm Fincap Pty Ltd.

The company said Dr Scrofani held a Master of Business Administration from the Melbourne Business School and Doctor of Philosophy from La Trobe University.

Race was up one cent or 0.6 percent to \$1.71.

### CAMBIUM (FORMERLY REGENEUS)

Cambium says it has revised chief executive officer Karolis Rosickas engagement and will pay him \$US325,000 (\$A479,833) a year for a four-day work week.

Cambium said the change was effective from July 1, 2024 and include short term incentives of up-to 220 percent of total fixed remuneration over three years, subject to performance, as well as a \$US150,000 retention incentive if Mr Rosickas remained with the company until October 5, 2025.

The company said the Singapore-based Mr Rosickas would be entitled to four weeks of leave a year, as well as Singapore public holidays.

Cambium fell 1.5 cents or 4.3 percent to 33.5 cents.

### ONCOSIL MEDICAL

Oncosil says due to "unforeseen personal family issues" the effective date of Peter Hall's appointment as a non-executive director has been delayed to October 1, 2024.

Earlier this year, Oncosil said it had appointed Mr Hall as a non-executive director, effective by "the end of August 2024" (BD: Jul 15, 2024).

Oncosil was up 0.1 cents or 9.1 percent to 1.2 cents with 14.1 million shares traded.

### TISSUE REPAIR, FEDERAL TAKEOVERS PANEL

Tissue Repair says it has not received a meeting requisition.

On Thursday night, the Takeovers Panel said it received an application from Tissue Repair relating to a potential board spill request concerning (BD: Aug 30, 2024).

The Panel said on August 27, 2024, Tissue Repair's "non-executive directors received notices under sections 249D and 203D dated August 15, 2024 to requisition a general meeting ... for the removal of two ... directors and the appointment of a new director".

The Takeovers Panel said the notices "were purportedly signed by shareholders asserting they collectively control more than 50 percent of [Tissue Repair's] voting shares [but Tissue Repair] submits that there are inconsistencies relating to the execution of the notices, which were signed via DocuSign".

The Panel said Tissue Repair alleged the shareholders had an agreement to restructure the board and did not disclose any combined voting power or relevant interests.

Today, Tissue Repair said that it "received a copy of a notice with an indication that, absent directors resigning and a new director being appointed, the actual meeting requisition would be formally served".

"To date, the actual requisition has not been received," Tissue Repair said.

Tissue Repair was up 4.5 cents or 10.7 percent to 46.5 cents.

## BIOTECH DAILY TOP 40 WITH MARKET CAPITALIZATION AT AUG 31, 2024

Company \$Am	Aug 31, 2023	Jul 31, 2024	Aug 31, 2024
Cochlear	17,826	22,596	19,419
CSL	131,942	149,673	148,808
Resmed	37,488	47,728	52,484
<b>BDI-20</b>			
Avita	636	392	343
Clinuvel	949	749	772
Compumedics	35	55	57
Cyclopharm	225	174	153
Cynata	23	45	35
Genetic Signatures	62	181	170
Immutep	338	501	588
Impedimed	363	125	97
Medical Developments	76	36	46
Mesoblast	415	1,165	1,085
Nanosonics	1,268	954	945
Neuren	1,592	2,467	1,944
Nova Eye	39	54	48
Opthea	201	529	720
Polynovo	1,028	1,850	1,637
Pro Medicus	7,659	15,012	15,376
SDI	106	109	111
Starpharma	60	39	41
Syntara	29	41	44
Telix	3,527	6,385	6,184
<b>Second 20</b>			
4D Medical	231	197	181
Actinogen	45	193	122
Alcidion	159	101	97
Amplia	17	15	33
Aroa	292	217	188
Atomo	18	24	13
Clarity	285	1,985	2,280
Curvebeam	152	75	67
Dimerix	27	248	248
Emvision	131	171	185
Imugene	465	390	434
Medadvisor	126	278	245
Micro-X	57	45	35
Orthocell	79	81	80
Paradigm	171	86	86
Percheron	54	65	78
Prescient	65	33	35
Proteomics	106	118	108
Resonance	27	25	29
Universal Biosensors	51	42	43

\* Biotech Daily editor, David Langsam, owns shares in Acrux, Actinogen, Alcidion, Alterity, Amplia, BTC Health, Clarity, Cochlear, Control Bionics, Cynata, Nanosonics, Neuren, Patrys, Polynovo, Syntara and Telix and non-biotech stocks. Through Australian Ethical Superannuation he has an indirect interest in other companies: <https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/>. These holdings are liable to change.

**Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053**  
**email: [editor@biotechdaily.com.au](mailto:editor@biotechdaily.com.au); [www.biotechdaily.com.au](http://www.biotechdaily.com.au)**